Interview with Thierry Teil, Managing Director, UCB Russia
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Address: Shabolovka str. 10Building 2, floor 3RUS – 119048 Moscow,Russia
Tel: +7 495 644 3322
Web: http://www.ucb.com/worldwide/Russia
UCB started operations in 1994, and after 2 partnering agreements, started local activities in 2005, further building its presence with Schwarz Pharma integration in 2007
UCB has two legal entities based in Moscow
– UCB Russia LLC
– UCB pharma Logistics LLC
Around 200 employees in 2011
UCB has representatives in the top 26 cities of Russia
In-market sales ~EURO 48 M in 2010
New legal entity: UCB Pharma Logistics
– Registred in 2010, Licenses granted, operational start in May. 2011
– Importation of UCB products in Russia and sales to distributors
– Partnership with a Russian distribution company FARMAT
Local manufacturing and packaging with Binnopharm
– Secondary packaging for a selected few products at the beginning
– Primary and secondary packaging planned
– Local manufacturing planned for later
– On-going finalization for this partnership on Local production, marketing and sales.
UCB Mature Products Continue to Improve Patients Outcome:
– Keppra :
Acknowledged worldwide as a landmark in the treatment of epilepsy, Keppra® is contributing to the wellbeing of thousands of Russian patients with epilepsy
-Xyzal and Zyrtec:
Bringing relief to patients with allergies, from allergic rhinitis to Chronic urticaria, in children and adults
-Isoket:
Leading nitrates in Russia for the treatment of angina pectoris with particularly helpful use in ambulances for Isoket ® spray
-Prostavasin:
Market leading treatment in conjunction to surgery for patients with Advanced Peripheral Obstructive Arterial disease as an alternative to amputation
All UCB Core Products in Russia: 2010-2011
UCB is becoming the Patient-Centric global biopharmaceutical leader
-Cimzia:
Fast response for predictable outcomes
-Vimpat:
When monotherapy is no longer enough
Launch in Russia in Sept 2010Already more than 300 severe epileptic patients treated
-Neupro:
24h continuous delivery by transdermal patch
Approval in Russia expected in July 2011 for Parkinson Disease
On-going launch following Phase 3 in Russia that has proven Cimzia’s benefit locallyNew treatment opportunity for patients with RA
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
Last time Focus Reports met with you in 2006, the Russian pharmaceutical industry had enjoyed five straight years of growth. This growth has since continued through 2011. Can you provide…
There is a long history of trade between Russia and Britain. The Chamber of Commerce started in 1916. Can you outline how the organisation has evolved and its current role…
When the Russian Federation emerged from the former USSR in 1991 all the structures of the past social net that provided for the complete healthcare needs of citizens were…
See our Cookie Privacy Policy Here
